Muhammad Furqan is an Oncology physician. ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
800 NE 10th St Ste B
Oklahoma City, OK 731045418
Telephone
405-271-4022Provider last certified this registry record 20 Oct 2025.
Clinical trials
- Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Sponsor: National Cancer Institute (NCI)
- Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
Sponsor: CellSight Technologies, Inc.
- Test-retest Evaluation of [18F]F-AraG PET
Sponsor: CellSight Technologies, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech USA, Inc.Program year20251 payment
- ABBVIE INC.Program year20241 payment
- Merck Sharp & Dohme LLCProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
37.7%Atypical Antipsychotic13%Olanzapine100%Part D≥54 patientsPhenothiazine10.7%Prochlorperazine Maleate100%Part D≥74 patients+ 4 more classes in this area
Metabolism & gastrointestinal
21.5%Serotonin-3 Receptor Antagonist9.8%Ondansetron Hcl100%Part D≥73 patientsProton pump inhibitor6.2%Pantoprazole Sodium72%Omeprazole28%Part D<11 patients+ 2 more classes in this area
Blood & clotting
11.5%Factor Xa inhibitor11.5%Eliquis64%Xarelto36%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2025–2026 per NIH RePORTER. The latest:
- A Lead Academic Participating Site in Oklahoma for the Design and Conduct of NCTN Clinical Trials
University of Oklahoma Hlth Sciences Ctr
FY2026$1,290,000UG1CA233193 - A Lead Academic Participating Site in Oklahoma for the Design and Conduct of NCTN Clinical Trials
University of Oklahoma Hlth Sciences Ctr
FY2025$1,744,559UG1CA233193
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”